The White House today announced the creation of the Patient-Empowered Precision Medicine Alliance (PEMPA)
PEMPA Aims to Match Patients and Therapies
The White House highlighted this new alliance in a discussion of its Precision Medicine Initiative, a research effort announced in 2015 and aimed at revolutionizing the treatment of disease through approaches that consider differences in people’s genes, environments, and lifestyle. PEPMA supports this national effort, as it seeks to substantially decrease the time and cost associated with matching patients to personalized drug therapies.
“We are proud to be a member of the Patient-Empowered Precision Medicine Alliance (PEPMA) and honored that the White House has recognized Pairnomix as a stakeholder in its Precision Medicine Initiative,” said Matthew Fox, CEO of Pairnomix. “We look forward to working with our partners in the alliance, along with patients and physicians, to advance the field of precision medicine.”
The Alliance will apply cutting-edge technologies in genomic medicine, data science, bioinformatics and rapid drug screening to find the right drug for the right patient. Ultimately, the alliance seeks to advance the methods of precision medicine, develop the resources needed to bring those methods into the clinical setting, and improve the cost curve in the process.
Each organization within PEPMA will play a specific, complementary role in partnering with patients and physicians to quickly identify more individualized therapies:
- Harvard Medical School Department of Biomedical Informatics will serve as a port of entry for patients through its patient coordinating center. The Department will also offer its expertise in bioinformatics-driven drug repurposing.
- Boston Children’s Hospital’s Manton Center for Orphan Disease Research will employ its expertise in the study of rare and unknown conditions to facilitate efforts to diagnose the undiagnosed.
- The University of Utah’s College of Pharmacy will build a team that focuses on using genomics to quickly match patients to medication regimens specific to their disease.
- Recursion Pharmaceuticals will provide big-data-driven personalized assay development for rapid repurposing screens.
- Pairnomix will construct laboratory models of individual genetic mutations and perform highly personalized drug screenings.
Pairnomix™, a genetic research company, is committed to helping people living with rare diseases understand the genetic roots of their condition. Pairnomix’ initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit pairnomiqstate.wpengine.com.
Pairnomix is guided by international leaders in the fields of neurology and genetics with input from experienced business executives. Dr. David Goldstein is Founding Scientist & Chair of Pairnomix’ Advisory Board. He serves as Professor of Genetics and Development in the College of Physicians and Surgeons and Director of the Institute for Genomic Medicine at Columbia University (NY). He is joined by:
- Dr. Orrin Devinsky, Director of the NYU Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery (INN). He is also a practicing physician and Professor of Neurology, Neurosurgery and Psychiatry at NYU Langone School of Medicine.
- Dr. Steven Petrou, Professor at the University of Melbourne, Australia. He is Deputy Director, Head of the Florey’s Division of Epilepsy, and is a neuropharmacologist.
- Dr. Matt Might, Associate Professor in the School of Computing at the University of Utah, where he works on cybersecurity, scientific computing and foundational research in programming languages.
- Dr. Slavé Petrovski, who received his PhD from the University of Melbourne, Australia and has a combined Bachelor of Information Systems and Bachelor of Science. He is currently a computational geneticist at the University of Melbourne.
- Mark Flynn, President of GSV Capital, a publicly traded fund focused on identifying and investing in rapidly growing late stage venture capital-backed private companies.
- Gray Knowlton, Chief Information Officer of Upsher-Smith Laboratories. He leads technology initiatives in support of operating plans and long-term business strategy.
MAPLE GROVE, Minn., February 25, 2016 /PRNewswire/